Monitor for further leadership changes or strategic shifts given the recent proxy fight context. The new CDO's background in pharmaceutical development may signal pipeline prioritization, but the low market cap suggests high execution risk.
Price Chart
Executive Summary
Plus Therapeutics appointed Dr. Eric J. Daniels as Chief Development Officer effective April 20, 2026, with a compensation package including a $460,000 base salary, 40% target bonus, and equity grants. This follows a contested proxy vote for board control, suggesting strategic leadership changes amid corporate governance tensions.
Key Facts
- Appointed Dr. Eric J. Daniels as Chief Development Officer effective April 20, 2026
- Compensation includes $460,000 annual base salary, 40% target bonus, 20,000 stock options, and 20,000 RSUs
- Stock options vest monthly over four years with one-year cliff; RSUs vest quarterly over three years with one-year cliff
- Severance package provides 12 months of salary plus target bonus if terminated without cause or resigned for good reason
- Follows contested DEFA14A proxy vote nine days prior indicating board control dispute
Financial Impact
Approximately $184,000 in annual cash compensation (salary + target bonus) plus equity grants valued at the grant date fair market value
Risk Factors
- High executive turnover risk following contested board election
- Dilution from new equity grants in a $22M market cap company
- Integration risk of new leadership amid corporate governance tensions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-148920 |
| Document: pstv-20260408.htm | 0001193125-26-148920 |
| Document: 0001193125-26-148920-index-headers.html | 0001193125-26-148920 |
| Document: 0001193125-26-148920-index.html | 0001193125-26-148920 |
| Document: 0001193125-26-148920.txt | 0001193125-26-148920 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 13w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 16w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 22w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 25w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 26w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers